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Chikungunya virus (CHIKV) is a reemerging alphavirus that causes acute febrile illness and severe joint pain in humans. Although
acute symptoms often resolve within a few days, chronic joint and muscle pain can be long lasting. In the last decade, CHIKV has
caused widespread outbreaks of unprecedented scale in the Americas, Asia, and the Indian Ocean island regions. Despite these out-
breaks and the continued expansion of CHIKV into new areas, mechanisms of chikungunya pathogenesis and disease are not well
understood. Experimental animal models are indispensable to the field of CHIKV research. The most commonly used experimental
animal models of CHIKV infection are mice and nonhuman primates; each model has its advantages for studying different aspects
of CHIKV disease. This review will provide an overview of animal models used to study CHIKV infection and disease and major
advances in our understanding of chikungunya obtained from studies performed in these models.
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Chikungunya virus (CHIKV) is a mosquito-transmitted positive-
sense RNA virus in the Alphavirus genus in the family Togavir-
idae. The hallmark symptoms of CHIKV infection in humans
are debilitating arthralgia that affects the peripheral joints, caus-
ing intense pain and swelling, high fever, and sometimes rash [1].
These symptoms may resolve within a few days, but many pa-
tients experience recurring disabling arthritic pain for months
to years [2, 3]. The long-term chronic arthralgia can have an
enormous impact on the individual’s quality of life [4, 5].
CHIKV can cause widespread outbreaks in areas where there
are competent mosquito vectors and CHIKV-naive popula-
tions, as demonstrated by the recent CHIKV outbreak in the
Americas. The first reported cases of local CHIKV transmission
in the Americas occurred in Saint Martin, a Caribbean island
[6]. Since then, CHIKV has rapidly spread throughout the Ca-
ribbean and to countries in Central and South America causing
>1.7 million cases [7]. Following a large outbreak, CHIKV may
disappear for years to decades, most likely because of a lack of
susceptible hosts [8]. At a later time, CHIKV can reemerge in
regions that no longer have preexisting CHIKV immunity [8].
CHIKV infects other species, such as nonhuman primates, that
can maintain the virus in a sylvatic enzootic transmission cycle
involving forest-dwelling Aedes mosquitoes.
HUMAN CHIKUNGUNYA
Acute chikungunya symptoms in humans appear 3–12 days after
a bite by an infected mosquito [9]. The most common acute
symptoms are sudden onset of fever, polyarthralgia, headache,
myalgia, rash, and fatigue [1, 9]. The arthralgia usually occurs in
>1 joint, particularly in peripheral joints (wrists, fingers, ankles,
and toes) [10]. Viral titer peaks within the first few days of symp-
tom onset and can persist as long as 12 days [9]. Newborns and
seniors (>60 years), who tend to have higher viral load, are at risk
for severe acute infection and usually exhibit more-severe, atypical
symptoms of CHIKV infection, such as skin lesions, encephalitis,
seizures, and blindness [1, 10–12]. The case-fatality rate following
CHIKV infection is relatively low (approximately 1:1000), and
many of these cases involved elderly patients [13]. The convales-
cent phase of CHIKV infection is associated with resolution of
fever and viremia and induction of adaptive immunity. Although
other acute symptoms resolve, joint and muscle pain may remain
for weeks to years [2,14,15].Roughly 43%–75% of CHIKV-infected
patients experience persistent/recurring symptoms, includ-
ing fatigue and joint pain, stiffness, and swelling, for about
2 years following CHIKV infection [3]. Risk factors for develop-
ing chronic joint pain after acute CHIKV infection include in-
creased age and disease severity during the acute stage [14–16].
The ability of CHIKV to replicate and persist in the joints and
muscle tissues over the long term is still debated in the field.
CHIKV antigen was detected in synovial and muscle tissue of
patients experiencing chronic arthritic pain [14, 17].
Although this is suggestive of persistent CHIKV replication,
more research is needed to increase the understanding of
chronic chikungunya-induced joint and muscle pain. Despite
its increasing spread worldwide, many details of chikungunya
pathogenesis are not well understood. Therefore, there is increasing
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Mouse models are a powerful resource for studying chikungunya
pathogenesis and as early-stage testing platforms for evaluating
CHIKV vaccines and therapeutics. Several attributes make mice
attractive model systems for studying CHIKV, including (1) their
relatively low cost; (2) the ease of housing, owing to their small
size; (3) the availability of large panels of mouse-specific reagents,
such as immune reagents, for quantifying the host response to
CHIKV infection; (4) the availability of inbred lines, which allows
genetically identical sets of mice to be used to assess phenotypic
reproducibility or to test the response against different treatments
in the same line; and (5) the availability of genetically modified
mice, such as single-gene-knockout animals, which allow the role
of specific host genes or pathways during CHIKV infection to be
evaluated. These features have led to the wide use of various
mouse models for evaluating viral virulence determinants, char-
acterizing the host pathways that play protective or pathologic
roles during CHIKV infection, and assessing the efficacy and
safety of early stage CHIKV vaccines and therapeutics. However,
while mouse models are powerful resources, existingmouse mod-
els also have limitations when considering their ability to model
every aspect of CHIKV infection in humans. There are instances
in which mice do not reproduce specific aspects of human
CHIKV infection, owing to a lack of functional conservation
between mouse and human genes, and existing mouse models
do not fully reproduce key aspects of CHIKV disease, including
maternal/neonatal transmission, enhanced CHIKV disease in
elderly individuals, or chronic chikungunya, and opportunities
exist to develop new model systems that better reproduce these
aspects of human CHIKV disease.
Acute Infection Models
Acute CHIKV disease mouse models can roughly be broken
down into 3 categories: lethal neonatal challenge models,
immunocompromised models of lethal disease, and CHIKV
arthritis/myositis models. All 3 models have made valuable con-
tributions to our understanding of chikungunya pathogenesis
and have concurrently served as early stage testing platforms
for evaluating candidate CHIKV vaccines and therapies.
Lethal Neonatal Challenge Models
Neonatal mice are highly susceptible to CHIKV infection and, prior
to modern cell culture techniques, were standard tools for the iso-
lation and amplification of viruses such as CHIKV [18]. Neonatal
mice, which develop lethal encephalitis, have been used to model
human neonatal infection and provide a system for studying viral
and host factors that contribute to severe disease in neonates [19,
20]. In addition to their usefulness as pathogenesismodels, neonatal
mice are sensitive tools for testing the efficacy of CHIKV-specific
polyclonal and monoclonal antibodies (mAbs) or other therapeu-
tics because of their high sensitivity to CHIKV infection. Further-
more, because of their immature immune systems, neonatal mice
cannot be used to directly test vaccine efficacy, but they are useful
for testing the safety of live attenuated vaccines [21]. However, the
immature state of their immune systems and the fact that they rap-
idly succumb to lethal CHIKV disease significantly limit their use-
fulness for studying the pathogenesis of CHIKV-induced arthritis
or for testing CHIKV vaccines.
Immunocompromised Models of Lethal Disease
The type I interferon (IFN) system is essential in protecting
from systemic CHIKV; mice lacking a functional type I IFN
receptor or other key components of the type I IFN pathway
(eg, IRF3/IRF7) are highly susceptible to CHIKV infection
[19, 22–24]. Therefore, these mice are useful tools for studying
the role of the type I IFN system in CHIKV pathogenesis and
are highly sensitive lethal challenge models for testing the effi-
cacy of anti-CHIKV Abs or the safety and efficacy of CHIKV
vaccines, as illustrated by the studies of Plante et al and Pal
et al [25, 26]. However, type I IFN receptor–deficient mice
rapidly die of CHIKV infection, which limits their usefulness
for studying chikungunya pathogenesis.
Arthritis/Myositis Models
Immunocompetent adult mouse models of CHIKV-induced ar-
thritis are valuable systems both for studying the pathogenesis
of CHIKV-induced arthritis and for testing CHIKV vaccines
and therapies. Subcutaneous CHIKV infection in the footpad of
C57BL/6 mice results in a biphasic swelling response in the inoc-
ulated foot, with peaks occurring approximately 3 and 7 days after
infection. The inoculated foot also develops severe arthritis, ten-
donitis, and fasciitis, while the contralateral foot does not exhibit
swelling, and inflammatory changes are relatively milder [27, 28].
By using gene-specific knockout mice, a number of groups have
begun to identify host factors that play either protective or path-
ologic roles during CHIKV arthritis, including IFN-stimulated
genes such as ISG15 and IFIT1 [20, 29]. Likewise, knockout
mouse studies have proven useful for identifying host genes and
cell types, such as CD4+ T cells, that drive acute CHIKV-induced
pathology [30, 31]. In addition to enhancing our overall under-
standing of chikungunya pathogenesis, these models have been
useful for testing vaccines and therapies for their ability to protect
against CHIKV-induced arthritis [32, 33].
Chronic/Persistent Models
The progression to chronic musculoskeletal pain and inflammation
occurs in up to two thirds of CHIKV-infected patients. The mech-
anisms of chronic chikungunya pathogenesis are not well under-
stood. In a limited number of human studies, CHIKV antigen
and RNA have been detected in synovial tissue biopsy specimens
collected from patients with chronic joint pain, with CHIKV anti-
gen detected in perivascular macrophages [14]. CHIKV antigen
also was detected in muscle satellite cells in muscle biopsy tissue
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specimens collected from a patient during a relapse of chronicmus-
culoskeletal pain [17].
Accordingly, mouse models have begun to be used to investi-
gate the persistence of CHIKV infection and its association with
chronic disease. C57BL/6 mice inoculated in the footpad with a
clinical isolate of CHIKV showed detectable viral RNA in a vari-
ety of tissues at early time points after infection [30]. By 4 weeks
after infection, CHIKV RNA was cleared from many tissues but
remained detectable in joint-associated tissues and lymphoid tis-
sue, suggesting that these tissues support chronic CHIKV infec-
tion. In this study, viral RNA was detected in joint-associated
tissues for at least 16 weeks after infection. The persistence of
CHIKV in these mice was associated with persistent synovitis,
suggesting that chronic CHIKV infection may cause chronic
joint inflammation [30]. Although isolation of infectious virus
from these tissues during the chronic phase has so far been un-
successful, evidence suggests that CHIKV persists in these tissues
by low-level continuous replication [31]. It is currently unclear
whether CHIKV acquires adaptive mutations during infection
of mice that contribute to the development of persistence [31,
34]; an in-depth analysis of CHIKV sequence evolution in differ-
ent tissue compartments during the acute and chronic phases of
infection of wild-type mice is warranted.
Mouse models are also being used to define immunological
mechanisms that contribute to the control of CHIKV infection
and how these may be altered during persistence.Work by several
groups has defined important roles for the adaptive immune re-
sponse, particularly the B-cell response, in control of CHIKV in-
fection [30, 31, 34–36]. While the adaptive immune response
appears to limit but not fully clear CHIKV from musculoskeletal
tissues, B cell– and T cell–deficient mice do not die of CHIKV
infection despite supporting persistent viremia and elevated
viral burdens in a variety of tissues [30, 31, 34–36]. These data
suggest that innate antiviral responses limit CHIKV replication
independent of adaptive immunity.
As highlighted above, mouse models can be exploited to inves-
tigate both virologic and immunologic mechanisms that influence
chronic CHIKV infection and disease. However, these studies
have been performed in a narrow range of mouse strains, and
there remains a critical need to improve mouse models to reflect
the diverse manifestations of chronic CHIKV disease, which
range from post-chikungunya musculoskeletal disorders to post-
chikungunya de novo chronic inflammatory rheumatism [37]. In
support of this goal, preliminary studies in the Collaborative Cross
(CC), a highly diverse mouse genetic reference population [38],
found that different CC mouse lines exhibit a diverse array of re-
sponses to CHIKV infection, including CC mouse lines that are
resistant or highly susceptible to virus-induced swelling and
lines that exhibit disseminated inflammation following CHIKV
infection (K. Plante, J. Plante, M. T. Ferris, and M. T. Heise, un-
published data). Furthermore, the diversity of CHIKV disease
outcomes observed in the CC has led to the initial identification
of quantitative trait loci associated with variation in CHIKV disease
susceptibility within the CC, setting the stage for future studies an-
alyzing whether genes identified in the CC have relevance to
human disease. In addition to a need for models that better repre-
sent the diverse CHIKV disease outcomes observed in humans, a
need also exists for improved models for studying the impact of
aging on CHIKV disease, since aged individuals may be at greater
risk for developing severe acute or chronic CHIKV disease [14–16].
NONHUMAN PRIMATE (NHP) MODELS OF CHIKV
INFECTION
The first experimental NHP CHIKV infection models were tested
in the 1960s, using rhesus macaques (Macaca mulatta) and bon-
net macaques (Macaca radiata) [39, 40]. In these early studies,
CHIKV infection was assessed by the development and duration
of viremia, along with the presentation of clinical symptoms, in-
cluding fever. Recently, NHP CHIKV infection models have been
used to study chikungunya pathogenesis and as preclinical models
to evaluate the efficacy of vaccines and immunotherapeutics. The
breadth of models available has expanded to include new NHP
models using cynomolgus macaques (Macaca fascicularis) and
further development of the rhesus macaque model to recapitulate
CHIKV infection in aged and pregnant populations [41–43].
Cynomolgus Macaque Model of CHIKV Infection
CHIKV infection of cynomolgus macaques results in acute disease
signs and viremia that are similar to those observed in humans,
followed by viral persistence in some tissues up to 3 months
after infection [41]. High-dose infection (108 plaque-forming
units) resulted in meningoencephalitis and may recapitulate neu-
rologic disease in humans [41]. Viremia developed within 1 day
after infection, lasting until 6–7 days after infection, with tissue
dissemination observed 2 days after infection and peak viral
RNA loads reached 6 days after infection. Notably, virus remained
detectable in lymphoid organs until 3 months after infection and
in synovial and muscular tissues until 1.5 months after infection,
and infectious virus was recovered from the spleen, liver, and mus-
cle as late as 44 days after infection, indicating that the virus per-
sists for long periods [41]. The level and duration of viremia and
associated disease was dependent on the infecting dose of CHIKV.
During human CHIKV infection, leukopenia is also reported to
occur; this phenomenon was recapitulated in the cynomolgus ma-
caque model, with significant monocytopenia, lymphopenia,
granulocytosis, and thrombocytopenia occurring in infected ani-
mals as compared to uninfected control animals [41]. Limited as-
pects of the immune response to CHIKV-LR in cynomolgus
macaques have been studied. The plasma levels of a number of cy-
tokines and chemokines, including IFN-α/β, interleukin 6, mono-
cyte chemoattractant protein 1, and IFN-γ, correlated with peak
levels of viremia [41].Both immunoglobulin M and immunoglob-
ulin GCHIKV-specific Ab responses were detectable in this model
of CHIKV, and these Abs are capable of recognizing similar epitopes
as observed in humans [44, 45]. This model not only recapitulates
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common characteristics of CHIKV infection, but also provides evi-
dence for CHIKV persistence within NHP tissues.
Rhesus Macaque Model of CHIKV Infection
CHIKV infection of rhesus macaques resulted in peak viremia lev-
els 1–2 days after infection, lasting to an average of 6 days after
infection [42, 43, 46, 47], and high fever that coincided with rash
during the first week of infection [43]. Studies in rhesus macaques
completed by Pal et al by using CHIKV-specific mAbs generated
interesting insights into dissemination routes of CHIKV [47]. In
these studies, CHIKV-infected rhesus macaques were treated
with anti-CHIKV or control mAbs 1 and 3 days after infection.
Differences in viral loads between the anti-CHIKV mAb–treated
group and control group at 7 days after infection led to the spec-
ulation that CHIKV spreads from the site of infection, in the arm,
into the blood, where it then goes on to infect the spleen and heart,
followed by establishment in distal joints and muscles, the lungs,
and kidneys [48]. This study exhibits how the rhesus macaque
model of CHIKV infection can be used to answer mechanistic
questions about chikungunya pathogenesis and serve as a preclin-
ical model for testing novel anti-CHIKV therapeutics.
The immune responses to CHIKV have been characterized in the
rhesus macaque model, providing important insight into correlates
of protection during human infection. Frequency of innate immune
cells in the peripheral blood of infected animals revealed an increase
in monocytes/macrophages and all dendritic cell subsets after infec-
tion [43]. In general, T-cell and B-cell proliferative responses peaked
10–14 days after infection, with a second burst of proliferation oc-
curring 28 days after infection in thememory B-cell subset [43].The
B-cell response was followed by a CHIKV-specific Ab response
peaking around 21 days after infection [43]. We are still lacking
key pieces of information about the host-specific immune response
to CHIKV, especially adaptive immune components, but these stud-
ies provide insight into important CHIKV-specific immune control
mechanisms.
Aged NHP Model of CHIKV Infection
During the CHIKV outbreak in La Reunion, individuals within the
aged population (ie, those >45 years old) were at a greater risk of
developing more-severe CHIKV disease, including but not limited
to persistent CHIKV-associated rheumatic manifestations and even
mortality [14]. Increased age has been associated with immune sen-
escence with a decrease in the ability of the immune system to re-
spond to pathogens. An aged CHIKV NHP model was developed
in aged (>17 years old) rhesus macaques byMessoudi et al and pre-
sented in a study comparing viremia, clinical symptoms, and the
CHIKV-specific immune response between CHIKV-infected
adult (6–13 years old) and aged (>17 years old) rhesus macaques
[43]. In general, both innate and adaptive immune responses were
delayed and blunted in aged animals as compared to adult animals;
this correlated with CHIKV persistence in aged animals [43]. This
initial study, using the aged NHPmodel of CHIKV infection, iden-
tified key differences in the way that aged animals respond to
CHIKV infection as compared to adult animals and suggests that
a decline in the immune response, as a result of age, could be a fac-
tor leading to increased CHIKV disease severity. Future studies
using this model will further delineate the role that age plays in
CHIKV immunity and disease severity.
Pregnant NHP Model of CHIK Infection
Intrauterine CHIKV infections were first reported during the out-
break in the Indian Ocean region [49]. It is unknown whether this
newly reported mode of transmission is the result of increased case
reporting during the outbreak or potentially a result of increased
pathogenesis and/or changes in tissue tropism of the virus [49–
51]. These unanswered questions led to the development of a preg-
nant rhesus macaque model of CHIKV infection. In this model,
rhesus macaques aged 7–15 years at gestational days 121–132
were infected with CHIKV [42]. Viremia level peaked at 2–3 days
after infection, and pregnant animals developed fever and changes
in blood cell counts correlating with peak viremia levels. In addi-
tion, a limited number of animals developed joint swelling in the
wrist and/or ankle, and persistent viral RNA was detectable in
the spleen and lymph nodes of pregnant rhesus macaques 21
days after infection. Despite development of viremia and CHIKV
dissemination in maternal tissues, the fetal condition remained un-
affected, as monitored by fetal heart rate. Infectious CHIKV or viral
RNAwas not detected in fetal tissues or in the placenta. There were
also no histological changes to fetal tissues as a result of CHIKV
infection. The lack of CHIKV infection in fetal tissues confirms
that prepartum CHIKV did not occur. These data are consistent
with studies of CHIKV infection during pregnancy in humans,
which demonstrated that intrauterine transmission of CHIKV is
very rare during early pregnancy but is more common if mothers
are viremic in the week preceding delivery [42, 50]. This model can
be used to study not only mother-to-child transmission of CHIKV,
but also how CHIKV infections might differ depending on host
conditions. A better understanding of CHIKV-host interactions is
important to the process of studying chikungunya pathogenesis
and the development of new treatment options that can work for
a broad spectrum of individuals.
NHPs as Preclinical Models for Testing CHIKV Vaccines and
Immunotherapeutics
Live-attenuated, CHIKV/IRES, DNA, virus-like particle, forma-
lin-inactivated, and UV-inactivated formulations of CHIKV vac-
cines have all been tested in NHP CHIKV models. Similarities in
CHIKV infection outcome, physiology, and immune response
between humans and NHPs make them ideal models to test po-
tential vaccines and antiviral therapeutics. Cynomolgus ma-
caques may represent an ideal model to assess the safety of
live-attenuated virus vaccines. Multiple parameters have been
measured during NHP CHIKV infection to assess the effective-
ness of potential vaccines and immunotherapeutics at hindering
the development of CHIKV infections. These include quantifica-
tion of virus in circulation (ie, viremia), fever and hypothermia,
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rise in heart rate, and virus dissemination [46, 47, 52]. Antibody
therapeutics against CHIKV have been tested in a NHP model as
a postexposure treatment option for CHIKV infection [47].Anti-
CHIKV mAb treatment blocked viremia and decreased viral
RNA loads in tissue sites distal to the site of CHIKV infection.
In the arm muscles and axillary lymph nodes, no difference in
viral RNA loads was detected between the groups [47]. These dif-
ferences, or the lack thereof, provided key information about the
effectiveness of the mAbs to control virus dissemination and how
CHIKV disseminates through the body during a typical CHIKV
infection. In the future, other NHP models, such as aged and
pregnant rhesus macaque models, could also be used in preclin-
ical trials to assess the effectiveness of potential vaccines and im-
munotherapeutics under unique host conditions.
SUMMARY
CHIKV is a mosquito-transmitted alphavirus that causes debili-
tating joint and muscle pain. The polyarthralgia and myalgia can
last for months to years after acute infection, significantly influ-
encing the quality of life of those affected. CHIKV historically has
caused repeated outbreaks in sub-Saharan Africa and Southeast
Asia, and the virus recently emerged in the western hemisphere.
Despite the spread of CHIKV to 5 continents and millions of
CHIKV disease cases, many aspects of chikungunya pathogenesis
are still unknown. Thus, animal models to investigate mecha-
nisms of CHIKV replication and pathogenesis, to define immu-
nological responses to CHIKV infection, and to test novel
vaccines and antiviral therapeutics for efficacy against CHIKV in-
fection are indispensable to improve our understanding of this
virus and develop treatments that have the potential to improve
human health.
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